Printer Friendly

TRINITY BIOTECH ANNOUNCES MULTIYEAR DISTRIBUTION AGREEMENT FOR MEXICO, $4.5-MILLION CONFIRMED ORDER FOR AIDS TEST

 DUBLIN, Ireland, April 20 /PRNewswire/ -- Trinity Biotech plc (NASDAQ: HIVSY) announced a five-year distribution agreement with Panamerican Enterprises S.A. de C.V. for Mexico and Centra this agreement will result in excess of $25 million in sales in the first three years of the contract period.
 The first confirmed order from Mexico has been received for two million tests ($4.5 million) and calls for delivery starting in June 1993 and extending over 10 months with all shipments backed by letters of credit.
 "We're pleased with the association with Trinity Biotech," indicated Clayton M. Hardman, president of Panamerican, "and we feel that there's a great deal of demand for Trinity's rapid HIV blood test and saliva technology."
 The initial order specifies the Trinity test using whole blood from a finger prick as the sample. The contract specifies conversion to the saliva specimen as clinical trials are finished. The Trinity test provides results in about seven minutes and requires no laboratory equipment or sample preparation.
 "While Trinity is conducting clinical trials on its rapid, saliva- based tests, its current HIV blood test is generating an important stream of revenue," stated Trinity Vice Chairman Michael C. Hubbard. "Mexico is an important market in its own right. It is ideal in terms of logistics, since the Trinity tests are currently being manufactured in Mexico and are fully approved for sale there by the Mexican government."
 Trinity Biotech is an Ireland-based diagnostics company dedicated to the development of rapid, on-site, saliva tests for HIV and other sexually transmitted diseases.
 -0- 4/20/93
 /CONTACT: Michael Hubbard of Trinity Biotech, 503-227-0643; or Peter Dorfman of GCI Group, 212-546-2359, for Trinity Biotech/
 (HIVSY)


CO: Trinity Biotech; Panamerican Enterprises ST: IN: MTC SU:

SW-LM -- SE017 -- 8136 04/20/93 13:40 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1993
Words:296
Previous Article:PLUM CREEK TIMBER CO., L.P., ANNOUNCES INCREASE IN QUARTERLY DISTRIBUTION TO UNITHOLDERS AND HIGHER FIRST QUARTER EARNINGS
Next Article:STARBUCKS COFFEE COMPANY EXPANDS ROOTS IN PACIFIC NORTHWEST WITH NEW KENT ROASTING PLANT
Topics:


Related Articles
DISEASE DETECTION INTERNATIONAL INC. HAS SEVEN-MINUTE AIDS TEST APPROVED IN MEXICO
TRINITY BIOTECH PLC ANNOUNCES INITIAL PUBLIC OFFERING
DISEASE DETECTION INTERNATIONAL FILES 'IND' APPLICATION WITH FDA SEEKING APPROVAL TO BEGIN FORMAL CLINICAL STUDIES FOR SEVEN-MINUTE AIDS TEST
DISEASE DETECTION INTERNATIONAL INC. COMPLETES $4.5-MILLION FINANCIAL RESTRUCTURING
DISEASE DETECTION INTERNATIONAL TO COMMENCE U.S.A. CLINICAL TRIALS OF SEVEN-MINUTE, SEROCARD(R) HIV-1, AIDS TEST UNDER FDA 'IND' SUBMISSION
DISEASE DETECTION INTERNATIONAL REPORTS RECORD REVENUES AND PROFITS FOR FISCAL 1992 AND SIGNIFICANT FORECASTS FOR 1993 AND BEYOND
DISEASE DETECTION INTERNATIONAL TO SUPPLY 1.2 MILLION TESTS IN BRASILIAN FEDERAL AIDS PROGRAM FOR THE STATE OF SAO PAULO, BRASIL
TRINITY BIOTECH ANNOUNCES RESIGNATION OF CHAIRMAN & CEO
TRINITY BIOTECH ANNOUNCES PRELIMINARY W.H.O. CLINICAL TRIAL RESULTS ON SEROCARD HIV-1/2 TEST
2 m deal will help US to fight disease.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters